More congressional interest in generic drugs
Consumer Interests Subcommittee of the House Select Committee on Aging has scheduled a March 1 hearing on the generic scandal. Chaired by Rep. Lloyd (D-Tenn.), the panel hopes to present "an accurate and balanced record" of the safety and efficacy of generics, according to staff. Witnesses are expected to include representatives of FDA and professional and trade associations.
You may also be interested in...
China’s first domestically-developed recombinant protein vaccine for COVID-19 moves forward in late-stage trials in two countries.
Splitting Colfax into separate fabrication technology and specialty medical technology businesses will help both sides of the business grow, CEO Matthew Trerotola said recently.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.